Literature DB >> 23935543

Environmental risk factors for inflammatory bowel disease.

Ashwin N Ananthakrishnan1.   

Abstract

Crohn's disease (CD) and ulcerative colitis (UC) are chronic immunologically mediated diseases that often have a relapsing-remitting course in young persons. Genetic-risk polymorphisms explain less than one third of the heritability of disease. Epidemiologic and laboratory data suggest that environmental factors play a significant role in influencing the risk and natural history of disease. Smoking is the most widely and consistently described risk factor. It, however, increases the risk of CD while conferring protection against UC. The gut microbiome is a key component in the development of inflammatory bowel disease (IBD). Several external factors potentially exert an effect by influencing the composition of the gut microbiome or disrupting the intestinal barrier. These external influences include the use of antibiotics or nonsteroidal anti-inflammatory drugs and the presence of enteric infections. Data on diet have been inconsistent, but high fiber intake, particularly of soluble fiber, appears to protect against CD, whereas protein intake may increase disease risk. Vitamin D may also play an important protective role, particularly in patients with CD. Neurobehavioral factors, such as stress and depression, also influence the risk of IBD. Systematic and rigorous studies of environmental exposures in the management of IBD are needed. In particular, studies of whether environmental factors can be modified to reduce the likelihood of relapse or improve patient outcomes would be valuable.

Entities:  

Keywords:  Crohn’s disease; cigarette smoking; diet; environmental factors; ulcerative colitis; vitamin D

Year:  2013        PMID: 23935543      PMCID: PMC3736793     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  84 in total

1.  High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease.

Authors:  Vidya M Raj Krishnamurthy; Guo Wei; Bradley C Baird; Maureen Murtaugh; Michel B Chonchol; Kalani L Raphael; Tom Greene; Srinivasan Beddhu
Journal:  Kidney Int       Date:  2011-10-19       Impact factor: 10.612

Review 2.  Genetics and pathogenesis of inflammatory bowel disease.

Authors:  Bernard Khor; Agnès Gardet; Ramnik J Xavier
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

3.  Low exposure to sunlight is a risk factor for Crohn's disease.

Authors:  V Nerich; P Jantchou; M-C Boutron-Ruault; E Monnet; A Weill; V Vanbockstael; G-R Auleley; C Balaire; P Dubost; S Rican; H Allemand; F Carbonnel
Journal:  Aliment Pharmacol Ther       Date:  2011-02-20       Impact factor: 8.171

Review 4.  Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence.

Authors:  Margherita T Cantorna; Brett D Mahon
Journal:  Exp Biol Med (Maywood)       Date:  2004-12

5.  An association between dietary arachidonic acid, measured in adipose tissue, and ulcerative colitis.

Authors:  Punyanganie S A de Silva; Anja Olsen; Jane Christensen; Erik Berg Schmidt; Kim Overvaad; Anne Tjonneland; Andrew R Hart
Journal:  Gastroenterology       Date:  2010-10-13       Impact factor: 22.682

6.  Mood disorders in inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors.

Authors:  J R Goodhand; M Wahed; J E Mawdsley; A D Farmer; Q Aziz; D S Rampton
Journal:  Inflamm Bowel Dis       Date:  2012-02-22       Impact factor: 5.325

7.  Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology of ulcerative colitis: a nested case-control study within a European prospective cohort study.

Authors:  A Tjonneland; K Overvad; M M Bergmann; G Nagel; J Linseisen; G Hallmans; R Palmqvist; H Sjodin; G Hagglund; G Berglund; S Lindgren; O Grip; D Palli; N E Day; K-T Khaw; S Bingham; E Riboli; H Kennedy; A Hart
Journal:  Gut       Date:  2009-07-23       Impact factor: 23.059

8.  Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study.

Authors:  S P Jørgensen; J Agnholt; H Glerup; S Lyhne; G E Villadsen; C L Hvas; L E Bartels; J Kelsen; L A Christensen; J F Dahlerup
Journal:  Aliment Pharmacol Ther       Date:  2010-05-11       Impact factor: 8.171

9.  Predicting relapse in Crohn's disease: a biopsychosocial model.

Authors:  A Bitton; P L Dobkin; M D Edwardes; M J Sewitch; J B Meddings; S Rawal; A Cohen; S Vermeire; L Dufresne; D Franchimont; G E Wild
Journal:  Gut       Date:  2008-04-07       Impact factor: 23.059

10.  Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection.

Authors:  Daniela Jodorkovsky; Yuki Young; Maria T Abreu
Journal:  Dig Dis Sci       Date:  2009-03-03       Impact factor: 3.199

View more
  39 in total

Review 1.  The Importance and Challenges of Dietary Intervention Trials for Inflammatory Bowel Disease.

Authors:  James D Lewis; Lindsey Albenberg; Dale Lee; Mario Kratz; Klaus Gottlieb; Walter Reinisch
Journal:  Inflamm Bowel Dis       Date:  2017-02       Impact factor: 5.325

Review 2.  The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions.

Authors:  Stephen M Vindigni; Timothy L Zisman; David L Suskind; Christopher J Damman
Journal:  Therap Adv Gastroenterol       Date:  2016-04-19       Impact factor: 4.409

3.  Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases.

Authors:  Betsy W Stevens; Nynke Z Borren; Gabriella Velonias; Grace Conway; Thom Cleland; Elizabeth Andrews; Hamed Khalili; John G Garber; Ramnik J Xavier; Vijay Yajnik; Ashwin N Ananthakrishnan
Journal:  Dig Dis Sci       Date:  2016-10-28       Impact factor: 3.199

4.  A Diet Low in Red and Processed Meat Does Not Reduce Rate of Crohn's Disease Flares.

Authors:  Lindsey Albenberg; Colleen M Brensinger; Qufei Wu; Erin Gilroy; Michael D Kappelman; Robert S Sandler; James D Lewis
Journal:  Gastroenterology       Date:  2019-03-11       Impact factor: 22.682

Review 5.  Inflammatory bowel disease and celiac disease: overlaps and differences.

Authors:  Virginia Pascual; Romina Dieli-Crimi; Natalia López-Palacios; Andrés Bodas; Luz María Medrano; Concepción Núñez
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

Review 6.  Advances in nutritional therapy in inflammatory bowel diseases: Review.

Authors:  Andrzej Wędrychowicz; Andrzej Zając; Przemysław Tomasik
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

7.  Zinc intake and risk of Crohn’s disease and ulcerative colitis: a prospective cohort study.

Authors:  Ashwin N Ananthakrishnan; Hamed Khalili; Mingyang Song; Leslie M Higuchi; James M Richter; Andrew T Chan
Journal:  Int J Epidemiol       Date:  2015-12       Impact factor: 7.196

Review 8.  Environmental and NSAID-enteropathy: dysbiosis as a common factor.

Authors:  Stephanie D Syer; John L Wallace
Journal:  Curr Gastroenterol Rep       Date:  2014-03

9.  A Novel Peroxisome Proliferator-activated Receptor (PPAR)γ Agonist 2-Hydroxyethyl 5-chloro-4,5-didehydrojasmonate Exerts Anti-Inflammatory Effects in Colitis.

Authors:  Jieun Choo; Yunna Lee; Xin-Jia Yan; Tae Hwan Noh; Seong Jin Kim; Sujin Son; Charalabos Pothoulakis; Hyung Ryong Moon; Jee H Jung; Eunok Im
Journal:  J Biol Chem       Date:  2015-09-04       Impact factor: 5.157

Review 10.  Pregnancy and inflammatory bowel diseases: Current perspectives, risks and patient management.

Authors:  Pegah Hosseini-Carroll; Monica Mutyala; Abhishek Seth; Shaheen Nageeb; Demiana Soliman; Moheb Boktor; Ankur Sheth; Jonathon Chapman; James Morris; Paul Jordan; Kenneth Manas; Felix Becker; Jonathan Steven Alexander
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.